BridgePoint Medical, Inc., a Plymouth, MN-based company developing innovative and proprietary technology in the field of interventional cardiology for crossing coronary and peripheral chronic total occlusions (CTO), has completed a$9.1m third round of financing.
The round was lead by a new strategic investor, with participation from existing investors New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman (the Chairman of the Board of directors).
The company intends to use the new funds to expand its marketing and sales efforts for BridgePoint’s CrossBoss™ Catheter and Stingray™ System in the United States, Europe and Japan through the use of distributors and direct sales.
Additionally, BridgePoint Medical will be initiating a U.S. IDE study of the technologies in peripheral artery disease in the first half of 2011.
The CrossBoss™ Catheter and Stingray™ System are designed to facilitate guidewire placement and subsequent dilatation balloon or Drug Eluting Stent (DES) placement in this challenging anatomy.
The company was established in 2006 to design, develop and commercialize new technologies and techniques to treat challenging coronary and peripheral artery disease.